Validea Detailed Fundamental Analysis

Validea's guru fundamental report assigns Johnson & Johnson (JNJ) an 88% rating under Partha Mohanram's P/B Growth Investor model, indicating high interest in the large-cap biotechnology and drugs stock. This growth strategy, developed from academic research demonstrating market outperformance, identifies low book-to-market stocks with attributes for sustained future growth, with JNJ largely meeting its stringent criteria despite a 'fail' in Research and Development to Assets.

Analysis

Johnson & Johnson (JNJ) has been assigned a high rating of 88% by Validea's P/B Growth Investor model, a quantitative strategy developed by Partha Mohanram to identify low book-to-market stocks with indicators of sustained future growth. This score, approaching the model's threshold for strong interest (90%), positions JNJ favorably as a large-cap growth stock within the Biotechnology & Drugs industry. The company successfully passed eight of the nine fundamental criteria, demonstrating strength in key areas such as Return on Assets (ROA), Cash Flow from Operations to Assets, and stability, as evidenced by passing the ROA Variance and Sales Variance tests. However, a notable weakness was identified, as JNJ failed the criterion for Research and Development to Assets. This single failure point warrants attention, especially for a company in a research-intensive sector, but the model's overwhelmingly positive score suggests that JNJ's other fundamental strengths, particularly in profitability and operational efficiency, currently outweigh this concern.

Key Decisions for Investors

• Investors with a growth-oriented mandate should view the 88% score from a historically outperforming model as a strong positive signal, indicating JNJ's alignment with criteria for sustained growth.
• The failure on the 'Research and Development to Assets' metric is a critical flag that requires further due diligence to assess its potential impact on JNJ's long-term innovation pipeline and competitive positioning.
• Given the stock's strong performance on metrics těžed to profitability and stability (ROA, cash flow, low variance), it may be considered for portfolios seeking quality growth with defensive characteristics, but the R&D expenditure level should be monitored季度-over-quarter.